Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP

Andrew L. Kung, Vivienne I. Rebel, Roderick T. Bronson, Lian Ee Ch'ng, Colin A. Sieff, David M. Livingston, Tso Pang Yao

Research output: Contribution to journalArticle

333 Scopus citations

Abstract

Mice with monoallelic inactivation of the CBP gene develop highly penetrant, multilineage defects in hematopoietic differentiation and, with advancing age, an increased incidence of hematologic malignancies. The latter are characterized, at least in some cases, by loss of heterozygosity (LOH) at the CBP locus. No such pathology was observed in wild-type or p300 heterozygous null mice of the same age and genetic background. Thus, a full complement of CBP, but not p300, is required for normal hematopoietic differentiation. These results also provide the first experimental evidence for the hypothesis that CBP has tumor-suppressing activity.

Original languageEnglish (US)
Pages (from-to)272-277
Number of pages6
JournalGenes and Development
Volume14
Issue number3
StatePublished - Feb 1 2000

Keywords

  • CBP
  • Hematopoiesis
  • LoH
  • Tumor suppressor
  • p300

ASJC Scopus subject areas

  • Genetics
  • Developmental Biology

Fingerprint Dive into the research topics of 'Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP'. Together they form a unique fingerprint.

Cite this